Improved sensitivity of an interferon-gamma release assay (T-SPOT.TB™) in combination with tuberculin skin test for the diagnosis of latent tuberculosis in the presence of HIV co-Infection

Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland.
BMC Infectious Diseases (Impact Factor: 2.56). 11/2011; 11:319. DOI: 10.1186/1471-2334-11-319
Source: PubMed

ABSTRACT Interferon-gamma release assays (IGRA) are more specific than the tuberculin skin test (TST) for the diagnosis of Mycobacterium tuberculosis infection. Data on sensitivity are controversial in HIV infection.
IGRA (T-SPOT.TB) was performed using lymphocytes stored within 6 months before culture-confirmed tuberculosis was diagnosed in HIV-infected individuals in the Swiss HIV Cohort Study.
64 individuals (69% males, 45% of non-white ethnicity, median age 35 years (interquartile range [IQR] 31-42), 28% with prior AIDS) were analysed. Median CD4 cell count was 223 cells/μl (IQR 103-339), HIV-RNA was 4.7 log10 copies/mL (IQR 4.3-5.2). T-SPOT.TB resulted positive in 25 patients (39%), negative in 18 (28%) and indeterminate in 21 (33%), corresponding to a sensitivity of 39% (95% CI 27-51%) if all test results were considered, and 58% (95% CI 43-74%) if indeterminate results were excluded. Sensitivity of IGRA was independent of CD4 cell count (p = 0.698). Among 44 individuals with available TST, 22 (50%) had a positive TST. Agreement between TST and IGRA was 57% (kappa = 0.14, p = 0.177), and in 34% (10/29) both tests were positive. Combining TST and IGRA (at least one test positive) resulted in an improved sensitivity of 67% (95% CI 52-81%). In multivariate analysis, older age was associated with negative results of TST and T-SPOT.TB (OR 3.07, 95% CI 1,22-7.74, p = 0.017, per 10 years older).
T-SPOT.TB and TST have similar sensitivity to detect latent TB in HIV-infected individuals. Combining TST and IGRA may help clinicians to better select HIV-infected individuals with latent tuberculosis who qualify for preventive treatment.

Download full-text


Available from: Matthias Cavassini, Jul 05, 2015
  • 10/2012; 22(5):701-2. DOI:10.1684/ejd.2012.1812
  • [Show abstract] [Hide abstract]
    ABSTRACT: Immunocompromised persons with latent tuberculosis infection are at increased risk for tuberculosis reactivation compared to the general population. Tuberculin skin test, the traditional assay for diagnosing LTBI (latent tuberculosis infection), has reduced accuracy in immunocompromised patients. Interferon-gamma release assays (IGRAs) are in vitro blood tests that measure T-cell release of interferon-gamma following stimulation by antigens unique to Mycobacterium tuberculosis. Here we review the data for the use of QuantiFERON-TB Gold In-Tube (QFT-GIT) and T-SPOT.TB, the two currently available IGRAs, in immunocompromised adults, including persons infected with HIV, patients with immune-mediated inflammatory disorders, candidates for treatment with TNF (tumor necrosis factor)-α inhibitors, patients receiving hemodialysis, solid-organ transplant recipients and patients with cancer. Based on the available data IGRAs have advantages over TST in specific patient populations and in certain situations. Further studies are needed to more accurately define the utility of IGRAs in immunocompromised patients.
    American Journal of Respiratory and Critical Care Medicine 12/2012; 188(4). DOI:10.1164/rccm.201209-1621CI · 11.99 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Pulmonary tuberculosis (TB) is a highly lethal infectious disease and early diagnosis of TB is critical for the control of disease progression. The objective of this study was to profile a panel of serum microRNAs (miRNAs) as potential biomarkers for the early diagnosis of pulmonary TB infection. Methods Using TaqMan Low-Density Array (TLDA) analysis followed by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) validation, expression levels of miRNAs in serum samples from 30 patients with active tuberculosis and 60 patients with Bordetella pertussis (BP), varicella-zoster virus (VZV) and enterovirus (EV) were analyzed. Results The Low-Density Array data showed that 97 miRNAs were differentially expressed in pulmonary TB patient sera compared with healthy controls (90 up-regulated and 7 down-regulated). Following qRT-PCR confirmation and receiver operational curve (ROC) analysis, three miRNAs (miR-361-5p, miR-889 and miR-576-3p) were shown to distinguish TB infected patients from healthy controls and other microbial infections with moderate sensitivity and specificity (area under curve (AUC) value range, 0.711-0.848). Multiple logistic regression analysis of a combination of these three miRNAs showed an enhanced ability to discriminate between these two groups with an AUC value of 0.863. Conclusions Our study suggests that altered levels of serum miRNAs have great potential to serve as non-invasive biomarkers for early detection of pulmonary TB infection.
    BMC Infectious Diseases 12/2012; 12(1):384. DOI:10.1186/1471-2334-12-384 · 2.56 Impact Factor